Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-31
2006-10-31
Powers, Fiona T. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S233000, C546S234000
Reexamination Certificate
active
07129251
ABSTRACT:
The invention describes novel nitrosated and/or nitrosylated H2receptor antagonist compounds, and novel compositions comprising at least one H2receptor antagonist compound that is optionally substituted with at least one NO and/or NO2group, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase and/or at least one nonsteroidal antiinflammatory drug, antacid, bismuth-containing reagent or anti-viral agent. The invention also describes methods for treating and/or preventing gastrointestinal disorders; improving gastroprotective properties of H2receptor antagonists; decreasing the recurrence of ulcers; facilitating ulcer healing; preventing and/or treating inflammations and microbial infections, ophthalmic diseases and disorders, multiple sclerosis, and viral infections; and decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds.
REFERENCES:
patent: 3950333 (1976-04-01), Durant et al.
patent: 4279906 (1981-07-01), Brown et al.
patent: 4293557 (1981-10-01), Shibata et al.
patent: 4705683 (1987-11-01), Dettmar
patent: 4742083 (1988-05-01), Richey
patent: 4900741 (1990-02-01), Kohler
patent: 5037815 (1991-08-01), Lukacsko et al.
patent: 5102902 (1992-04-01), Mercer
patent: 5112850 (1992-05-01), Benes et al.
patent: 5188839 (1993-02-01), Pearmain
patent: 5229134 (1993-07-01), Mention et al.
patent: 5403830 (1995-04-01), Place
patent: 5407688 (1995-04-01), Place
patent: 5476669 (1995-12-01), Borody
patent: 5541212 (1996-07-01), Bourinbaiar
patent: 5578597 (1996-11-01), Spector et al.
patent: 5656652 (1997-08-01), Davis
patent: 5703073 (1997-12-01), Garvey et al.
patent: 29 46 332 (1980-05-01), None
patent: 049618 (1982-04-01), None
patent: 0 164 040 (1985-12-01), None
patent: 224612 (1987-06-01), None
patent: 285681 (1988-10-01), None
patent: 743320 (1996-11-01), None
patent: 9407541 (1994-04-01), None
patent: 9733576 (1997-09-01), None
patent: 9857626 (1998-12-01), None
patent: 9944595 (1999-09-01), None
patent: 9945004 (1999-09-01), None
Bourinbaiar et al., Life Sciences, 59(23), PL 365-370, 1996.
Emerson et al., Nueroreport, 13(11), 1407-1410, Aug. 2002.
Hogan, J. Clin. Gastroenterol., 12 (Suppl. 2), S21-S28, 1990.
Ishikawa et al., European Journal of Pharmacology, 378, 299-310, 1999.
Raskin, The American Journal of Medicine, 106(5B), 3S-12S, May 31, 1999.
Siepler et al., Am. J. Hosp. Pharm., 35(2), 141-145, Feb. 1978.
Chemical Abstracts, 98:215341, 1983, “Phenoxyalkylamine Derivatives”, Teikoku Hormone Mfg, Co. Ltd., JP 58-015945, Jan. 29, 1983, Registry No. 85856-36-6.
Trzeciakowski et al., Journal of Ocular Pharmacology, 3(1), 55-61, Spring 1987.
Cohen et al., Canadian Journal of Ophthalmology, 19(5), 212-214, Aug. 1984.
Sekiguchi et al.,Arzneim. Forsch Drug Res., 43(1):134-138 (1993).
Ichikawa et al.,J. Pharmacol., 251:107-111 (1994).
Ivanov et al.,J. Pharmacol., 48:297-301 (1996).
Brunton,Goodman and Gilman, The Pharmacological Basis of Therapeutics, 9thEdition, 901-915 (1996) McGraw-Hill.
Marazova et al.,Pharm. Pharmacol., 49:791-795 (1997).
Ichikawa et al.,Brit. J. Pharmacol., 122:1230-1236 (1997).
Sorba et al.,Arzneim. Forsch Drug Res., 47:849-854 (1997).
Sekine et al.,Chem. Pharm. Bull., 46:610-615 (1988).
Hirakawa et al.,Chem. Pharm. Bull., 46:610-622 (1988).
Hassan et al, Analytica Chimica Acta, 332:39-48 (1996).
Franekic et al, Mutation Research, 227:13-16 (1989).
International Search Report for PCT/US99/27207.
Maltz, Clinical Bulletin, 9(4) :165-167 (1979).
Selker, The New England Journal of Medicine, 299(15) :834 (1978).
R Rice et al., Chemical Abstracts, 97:183, 1982.
Montzka et al., Canadian Journal of Chemistry, 61(8), 1771-1777, 1983.
DeFlora, Lancet, 2(8253), pp. 993-994, 1981.
Database HCAPLUS STN. XP002329205. Database accession No. 128:226033/DN. Mar. 18, 1998.
Database HCAPLUS STN. XP002329203. Database accession No. 92:58780/DN. May 12, 1984.
Foye, William O. et al. XP002329202. Principles of Medicinal Chemistry, 4th Ed. pp. 435-438. 1995.
Jul. 5, 2005. Supplementary European Search Report from European Patent Application No. 99962784.7.
Garvey David S.
Letts L. Gordon
Lin Chia-En
Wang Tiansheng
NitroMed Inc.
Powers Fiona T.
Wilmer Cutler Pickering Hale and Dorr LLP
LandOfFree
Nitrosated and nitrosylated H 2 receptor antagonist... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nitrosated and nitrosylated H 2 receptor antagonist..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitrosated and nitrosylated H 2 receptor antagonist... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3651604